Intercytex was originally founded in 2000 and listed on the Alternative Investment Market in February 2006. As a result of the recession and disappointing trial results with another product, Intercytex Group plc delisted from AIM, selling all of its assets and undergoing voluntary liquidation.
The Intercytex name and ICX-RHY were purchased by private investors and relaunched as Intercytex Ltd in 2010.
Today Intercytex Ltd is focused on developing ICX-RHY
The reformed company is headed up by Dr Paul Kemp, who is one of the pioneers in Regenerative Medicine and has over 25 years commercial experience in the field both in the US and UK The company is based in the Core Technology Facility in Manchester.